Medicare HSAs May Compel Drug Industry To Rethink Position On OTCs
This article was originally published in The Tan Sheet
Executive Summary
The growth of health savings accounts could force pharmaceutical companies to rethink their approach to OTC switches and consumer marketing, medical economist J.D. Kleinke told the Pharmaceutical Research & Manufacturers of America
You may also be interested in...
HSAs Could Be OTC Manufacturers’ Sleeping Giant Under Bush Health Plan
President Bush's healthcare plan, which prominently features health savings accounts (HSAs), may prove to be a bonanza for the nonprescription drug industry
FDA Guidances On Actual Use Studies, Switches Will Clarify Agency Processes
A guidance on conducting actual use trials for Rx-to-OTC switch candidates is under development, according to FDA Office of New Drugs Director John Jenkins, MD
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC